Navigation Links
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
Date:6/26/2012

hormone, and they further validate the dosing regimen for the company's planned Phase III trial. 

The study, Once-Weekly, CTP-Modified hGH (MOD-4023) Is Effective in Growth Hormone Deficient Adults: A Phase II Dose and Frequency Finding Study, was discussed in an oral presentation on June 25, 2012 by clinical investigators who oversaw the Phase II trial.  For more information on ENDO 2012, visit www.endo-society.org/endo.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

 Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned tha
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
4. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
5. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
8. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
9. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
10. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
11. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Safety, Proof of Mechanism of a Potential Oral Antagonist ... 20 Amira Pharmaceuticals, Inc., announced today the initiation ... internally discovered oral drug candidate for the treatment and ... arachidonic acid pathway.AM211 is an oral, selective antagonist of ...
... (Nasdaq: BNVI ) today announced the poster presentation ... compound and mechanism of action for its preclinical cancer drug ... conference of the American Association of Cancer Research (AACR) in ... , BN108, ...
... Group of AdvisorsSAN DIEGO, April 20 Trius Therapeutics, ... Board, naming Donald H. Batts, MD, FACP, FIDSA, and ... members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of Infectious ...
Cached Biology Technology:Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2
(Date:7/11/2014)... and Mineral Research awarded Michael F. Holick, PhD, MD, ... 2014 Louis V. Avioli Award. Holick, a professor of ... for revolutionizing the understanding of vitamin D and its ... a member of the American Society for Bone and ... mineral basic research. It is named for ASBMR,s first ...
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... PITTSBURGH, Jan. 3 Mice bred to age too quickly ... scientists at the University of Pittsburgh School of Medicine injected ... of young, healthy animals. Instead of becoming infirm and dying ... cells improved their health and lived two to three times ...
... line of attack against pancreatitis and pancreatic cancer is ... substantial new funding from the Medical Research Council (MRC). ... digestion turn on the pancreas itself. Chronic pancreatitis increases ... five-year survival rate of all common cancers in the ...
... kind, researchers at Queens College and Mount Sinai School ... and maternal gestational diabetes together may cause a 14-fold ... six year olds. The data are published in the ... Adolescent Medicine , one of the JAMA/Archives journals. ...
Cached Biology News:Pitt: A shot of young stem cells made rapidly aging mice live longer and healthier 2New stage in fighting pancreatic cancer 2Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2
... pump, available in a single and twin head, ... design. With the most compact, lightweight package in ... in portable air and gas applications., Available ... T2-01TH). , Delivers 1.5 and 2.0 liters per ...
... for the mechanical harvesting of cells • ... even contact with the growth surface • ... flasks • Individually wrapped • Sterilized by ... CLS number is a new product number, ...
... The Yeast ProtoArray high-density functional protein microarray ... rapid elucidation of proteinprotein interactions on a ... S. cerevisiae open reading frames (ORFs) expressed ... duplicate on a 1 inch x 3 ...
... Yeast nitrogen base (YNB) is a base medium ... media. YNB contains ammonium sulfate but does not ... pouches are available. Each pouch contains reagents ... Pichia media or 1000 ml of 10X YNB ...
Biology Products: